REVELATION BIOSCIENCES, INC. Operating Cash Flow
REVELATION BIOSCIENCES, INC. (REVB) reported Operating Cash Flow of -$5.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.56M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.21M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.97M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.59M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$8.27M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$18.32M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$7.29M.
- REVELATION BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$11.22M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.77M 10-Q · filed 2026-08-06 | -$7.74M derived: sum of 3 quarters · filed 2026-08-06 | -$9.33M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$3.21M 10-Q · filed 2026-05-07 | -$5.18M derived: sum of 2 quarters · filed 2026-05-07 | -$6.77M derived: sum of 3 quarters · filed 2026-05-07 | -$8.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.56M derived: sum of 2 quarters · filed 2026-02-26 | -$5.48M derived: sum of 3 quarters · filed 2026-08-06 | -$8.27M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.51M derived: sum of 2 quarters · filed 2026-08-06 | -$6.30M 10-Q · filed 2025-11-06 | -$10.05M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.71M 10-Q · filed 2026-08-06 | -$8.46M derived: sum of 3 quarters · filed 2026-08-06 | -$17.72M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$2.79M 10-Q · filed 2026-05-07 | -$6.54M derived: sum of 2 quarters · filed 2026-05-07 | -$15.80M derived: sum of 3 quarters · filed 2026-05-07 | -$18.28M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$13.00M derived: sum of 2 quarters · filed 2026-02-26 | -$15.48M derived: sum of 3 quarters · filed 2026-02-26 | -$18.32M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$9.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.74M derived: sum of 2 quarters · filed 2025-11-06 | -$14.57M 10-Q · filed 2025-11-06 | -$16.58M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$5.32M 10-Q · filed 2025-08-08 | -$7.32M derived: sum of 3 quarters · filed 2025-08-08 | -$9.04M derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-03-31 | -$2.84M 10-Q · filed 2025-05-08 | -$4.84M derived: sum of 2 quarters · filed 2025-05-08 | -$6.56M derived: sum of 3 quarters · filed 2025-05-08 | -$8.55M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$3.72M derived: sum of 2 quarters · filed 2025-03-06 | -$5.71M derived: sum of 3 quarters · filed 2025-03-06 | -$7.29M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-08 | -$3.71M derived: sum of 2 quarters · filed 2024-11-08 | -$5.28M 10-Q · filed 2024-11-08 | -$6.23M derived: sum of 4 quarters · filed 2024-11-08 | ||||
| 2023-06-30 | -$1.99M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-09-23 | -$3.57M 10-Q/A · filed 2024-09-23 | -$4.51M derived: sum of 3 quarters · filed 2024-09-23 | -$6.25M derived: sum of 4 quarters · filed 2024-09-23 | ||||
| 2023-03-31 | -$1.58M 10-Q/A · filed 2024-09-23 | -$2.52M derived: sum of 2 quarters · filed 2024-09-23 | -$4.25M derived: sum of 3 quarters · filed 2024-09-23 | -$7.96M derived: sum of 4 quarters · filed 2024-09-23 | ||||
| 2022-12-31 | -$947.47K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-23 | -$2.68M derived: sum of 2 quarters · filed 2024-09-23 | -$6.39M derived: sum of 3 quarters · filed 2024-09-23 | -$11.22M 10-K/A · filed 2024-09-23 | ||||
| 2022-09-30 | -$1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$5.44M derived: sum of 2 quarters · filed 2023-11-09 | -$10.27M 10-Q · filed 2023-11-09 | -$13.15M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$3.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$8.54M 10-Q · filed 2023-08-11 | -$11.42M derived: sum of 3 quarters · filed 2023-08-11 | -$13.65M derived: sum of 4 quarters · filed 2023-08-11 | ||||
| 2022-03-31 | -$4.83M 10-Q · filed 2023-05-22 | -$7.71M derived: sum of 2 quarters · filed 2023-05-22 | -$9.94M derived: sum of 3 quarters · filed 2023-05-22 | -$13.54M derived: sum of 4 quarters · filed 2023-05-22 | ||||
| 2021-12-31 | -$2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$5.11M derived: sum of 2 quarters · filed 2023-03-30 | -$8.71M derived: sum of 3 quarters · filed 2023-03-30 | -$11.09M 10-K · filed 2023-03-30 | -$725.62K 10-K · filed 2022-04-15 | |||
| 2021-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$5.83M derived: sum of 2 quarters · filed 2022-11-10 | -$8.21M 10-Q · filed 2022-11-10 | -$499.92K 10-Q · filed 2021-10-29 | -$8.42M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$5.98M 10-Q · filed 2022-08-15 | -$217.95K 10-Q · filed 2021-08-23 | -$6.19M derived: sum of 3 quarters · filed 2022-08-15 | -$6.19M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | -$2.38M 10-Q · filed 2022-05-16 | -$146.37K 10-Q · filed 2021-06-22 | -$2.59M derived: sum of 2 quarters · filed 2022-05-16 | -$2.59M derived: sum of 3 quarters · filed 2022-05-16 | -$2.61M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$208.12K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | -$208.98K derived: sum of 2 quarters · filed 2022-04-15 | -$231.35K derived: sum of 3 quarters · filed 2022-04-15 | -$216.66K 10-K · filed 2022-04-15 | -$218.71K 10-K · filed 2021-03-31 | |||
| 2020-09-30 | -$868.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | -$23.24K derived: sum of 2 quarters · filed 2021-10-29 | -$8.55K 10-Q · filed 2021-10-29 | |||||
| 2020-06-30 | -$22.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-23 | -$7.68K 10-Q · filed 2021-08-23 | ||||||
| 2020-03-31 | $14.69K 10-Q · filed 2021-06-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |